OPR - Delayed Quote • USD MDGL May 2024 390.000 call (MDGL240517C00390000) Follow 6.20 0.00 (0.00%) At close: March 18 at 3:41 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for MDGL240517C00390000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: MDGL Madrigal Statement on the Passing of Dr. Stephen Harrison Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Latest Insider Selling in April 2024: 10 Stocks to Watch Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares 1 No-Brainer Growth Stock to Buy Now The 3 Best Biotech Stocks to Buy in April 2024 Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
